Sun pharma ties up with China’s HitGen for molecular discovery

By: |
March 13, 2019 1:29 PM

HitGen Chairman of the board and chief executive officer Jin Li said the company will work closely with SPARC scientists to generate novel leads for their innovative research programmes to address unmet medical needs

The statement, however, did not elaborate on details of the payments.

Sun Pharma’s research arm Sun Pharma Advanced Research Company (SPARC) and China’s biotech firm HitGen Wednesday announced a collaboration to identify novel small molecule leads for targets of interest. Under the terms of the agreement, HitGen will receive upfront payment and will be eligible for certain milestone payments.

“Under this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for SPARC,” both companies said in a joint statement. The statement, however, did not elaborate on details of the payments.

HitGen Chairman of the board and chief executive officer Jin Li said the company will work closely with SPARC scientists to generate novel leads for their innovative research programmes to address unmet medical needs. HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China, and a subsidiary in the USA. Shares of SPARC were trading 2.08 percent higher from its previous close at Rs 200.80 apiece on BSE.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1L&T donates 24 ventilators to hospitals in south Gujarat
2Fintechs pick up MDR tab, enjoy merchant’s float
3Q4 earnings: IT firms take lead as India Inc turns in good numbers